Moberg Pharma´s interim report January - March 2024
LAUNCH INITIATED IN SWEDENFIRST QUARTER (JAN-MAR 2024) · Net revenue SEK 0.8 million (0) · EBITDA SEK -7.6 million (-6.1) · Operating profit (EBIT) SEK -7.9 million (-6.7) · Profit after tax SEK -6.5 million (-5.0) · Diluted earnings per share SEK -0.23 (-0.51) · Cash and cash equivalents amounted to 38.6 million (84.5) SIGNIFICANT EVENTS IN THE FIRST QUARTER · The sale of MOB-015 in Sweden under the brand name Terclara® has begun in collaboration with the company’s partner Allderma and the majority of pharmacies around the country have decided to sell the